Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20764818 | 1.00 | MEN1 (0.34) | MEN1KMT2ACCNA2CDK2CCNA1 | |
| SCHEMBL29397787 | 0.88 | ALDH1A1 (0.33) | MEN1KMT2AALDH1A1 | |
| SCHEMBL1610399 | 0.86 | MEN1 (0.37) | MEN1KMT2ATDP1ALDH1A1SLC6A3 | |
| SCHEMBL29399995 | 0.85 | CA1 (0.36) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4633132 | 0.84 | MEN1 (0.34) | MEN1KMT2ACCNA2CDK2CCNA1 | |
| SCHEMBL29870181 | 0.84 | ALDH1A1 (0.34) | MEN1KMT2AALDH1A1 | |
| SCHEMBL29870007 | 0.83 | NAAA (0.35) | MEN1KMT2AALDH1A1 | |
| SCHEMBL10704941 | 0.83 | NAAA (0.35) | MEN1KMT2AALDH1A1 | |
| SCHEMBL29397857 | 0.82 | EPHX1 (0.33) | MEN1KMT2ASLC6A3EPHX1 | |
| SCHEMBL8078214 | 0.80 | MAPT (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099433-A1 | COMPOSITION AND METHOD FOR TREATMENT OF GRAM NEGATIVE BACTERIAL INFECTION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2019038362-A1 | ANTIBACTERIAL PYRROLOIMIDAZOLONES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-02-28 | — | — | WO | disclosed |
| EP-3386950-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017098440-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| EP-2961741-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | Fundacion para la Investigacion Medica Aplicada (ES) | 2016-01-06 | — | — | EP | disclosed |
| WO-2014131855-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2014-09-04 | — | — | WO | disclosed |
| EP-2512474-A1 | N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| EP-2488489-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011045703-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099433-A1 | COMPOSITION AND METHOD FOR TREATMENT OF GRAM NEGATIVE BACTERIAL INFECTION | NR1H3, NR1H4, NR1H2 | MEN1 4056/4885KMT2A 2714/4885CCNA2 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.